Omeros | OMER - Ebitda


Omeros reported $-47.96M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Adma Biologics USD 58.74M 14.75M Sep/2025
Alnylam Pharmaceuticals USD 381.78M 362.95M Sep/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Cytokinetics USD -107.82M 45.51M Jun/2025
Dynavax Technologies USD 35.53M 10.9M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Insmed USD -297.13M 71.11M Jun/2025
Knight Therapeutics CAD 15.51M 3.39M Jun/2025
MacroGenics USD 21.95M 55.39M Sep/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 49.36M 4.96M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xoma USD 2.52M 7.98M Jun/2024